425: BioNTech to Acquire CureVac, Expanding mRNA Oncology Focus

BioNTech SE launches an exchange offer to acquire all issued ordinary shares of CureVac N.V. in a stock-for-stock transaction, aiming to expand its mRNA oncology capabilities.

Summary

• BioNTech SE is offering to acquire all issued ordinary shares of CureVac N.V. (Nasdaq: CVAC) in exchange for newly registered American Depositary Shares (ADSs) of BioNTech (Nasdaq: BNTX).
• The exchange ratio is determined by dividing $5.4641 by the BioNTech ADS Volume-Weighted Average Price (VWAP) over a ten-trading-day period, with collar adjustments: 0.04318 if BNTX VWAP is greater than or equal to $126.55, and 0.06476 if BNTX VWAP is less than or equal to $84.37.
• For any fractional Offer ADSs, tendering CureVac shareholders will receive an equivalent amount in cash.
• The offer commences on October 21, 2025, at 4:00 p.m. (New York City time) and will initially remain open until December 3, 2025, at 9:00 a.m. (New York City time).
• The acquisition is expected to provide significant strategic benefits, including furthering BioNTech's mRNA strategy in oncology and expanding its capabilities in target discovery, production, mRNA design, and delivery formulations.
• Shareholders representing approximately 57% of CureVac Shares have entered into tender and support agreements.
• The total cost related to the Offer is estimated at approximately €17.5 million.
• BioNTech expects to incur a net loss for the financial year 2025, with projected revenues between €1.7 billion and €2.2 billion, R&D expenses between €2.6 billion and €2.8 billion, and sales, general and administrative expenses between €650.0 million and €750.0 million.
• CureVac reported revenues of €535.180 million and a net profit of €162.186 million for the year ended December 31, 2024. For the six months ended June 30, 2025, CureVac reported revenues of €2.138 million and a net loss of €111.644 million.

Sentiment

Score: 4

Explanation: While the acquisition of CureVac and the BMS collaboration offer significant strategic potential and substantial upfront payments, BioNTech's current financial performance shows significant net losses and declining COVID-19 vaccine revenues. The company faces numerous ongoing legal challenges and the inherent high risks of pharmaceutical development, including clinical trial failures and regulatory uncertainties. The dilution for existing shareholders and the potential for further capital raises also contribute to a cautious outlook.

Positives

• The acquisition of CureVac is expected to significantly support BioNTech's global mRNA strategy in oncology, expanding capabilities in target discovery, production, mRNA design, and delivery formulations.
• The transaction complements BioNTech's recent acquisitions in other key oncology pillars, such as immunomodulators and antibody-drug conjugates.
• BioNTech maintains a strong financial position with approximately €15.989.3 million in total cash, cash equivalents, and security investments as of June 30, 2025.
• A global co-development and co-commercialization agreement with Bristol Myers Squibb (BMS) for BNT327 includes a $1.5 billion upfront payment, $2 billion in non-contingent anniversary payments through 2028, and up to $7.6 billion in additional development, regulatory, and commercial milestones.
• BNT327, a bispecific antibody, has shown encouraging clinical activity in various tumor types, including those less responsive to current checkpoint inhibitors.
• BNT211, a CAR-T cell therapy, has been granted Priority Medicines (PRIME) designation by the EMA and Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
• BNT316/ONC-392, an anti-CTLA-4 monoclonal antibody, received Fast Track Designation from the FDA for advanced endometrial cancer.
• BioNTech continues to demonstrate leadership in COVID-19 vaccine development, distributing approximately 180 million doses in 2024 and focusing on new variant-adapted vaccines.
• The company is committed to equitable access to medicine, with over 30% of Comirnaty doses delivered to lowand middle-income countries in 2024.
• An expanded strategic partnership with CEPI will establish RNA vaccine manufacturing capabilities in Kigali, Rwanda, supported by up to $145 million in funding.
• BioNTech's near-term science-based emission reduction targets (42% absolute scope 1 and 2 GHG reduction by 2030 from a 2021 base year) were approved by the Science Based Targets initiative (SBTi).
• BioNTech improved its overall ESG rating from Bto B in the Corporate Rating 2024 by S&P Global and maintained its Prime status from ISS ESG (Top 10% in its sector).
• Successful settlement agreements with NIH ($791.5 million payment) and UPenn (up to $467.0 million payment) resolved significant contingent liabilities.
• Settlement arrangements with GSK and CureVac resolved pending patent litigation in the US, granting BioNTech a non-exclusive license for mRNA-based vaccines.
• The United States Patent Trial and Appeal Board (PTAB) found all challenged claims of Moderna's U.S. Patent Nos. 10,933,127 and 10,702,600 to be unpatentable and thus invalid.

Negatives

• BioNTech expects to report a net loss for the financial year 2025.
• The company incurred significant net losses of €802.4 million in the first six months of 2025 and €665.3 million for the full year 2024.
• Operating losses were substantial, reaching €1,035.2 million in H1 2025 and €1,314.3 million in 2024.
• COVID-19 vaccine revenues are declining due to waning demand, leading to inventory write-downs and cancellations of contract manufacturing orders.
• Research and development expenses remain high (€1,034.7 million in H1 2025, €2,254.2 million in 2024), contributing to overall losses.
• Sales, general and administrative expenses are increasing (€258.0 million in H1 2025, €599.0 million in 2024).
• The finance result decreased in H1 2025 due to lower interest income and negative foreign exchange differences.
• The acquisition of CureVac will result in dilution for existing BioNTech shareholders, with their percentage decreasing by approximately 4.0% to 5.9%.
• CureVac shareholders who do not tender their shares may be subject to Dutch dividend withholding tax on the cancellation consideration.
• CureVac reported a net loss of €111.644 million for H1 2025 and faces risks of repaying up to €450 million of an upfront payment to the EU Commission.
• Integration of CureVac poses risks, including the inability to realize anticipated synergies, potential tax liabilities, management distraction, and challenges in retaining key employees.
• Counterparties to certain CureVac agreements may exercise termination rights due to the change of control.
• Substantial expenses are expected in connection with the CureVac acquisition, estimated at approximately €17.5 million.
• The Phase 2 clinical development of BNT211 in germ cell tumors has been discontinued due to portfolio prioritization.
• Development programs for BNT315/GEN1055 and BNT322/GEN1056 have been discontinued due to strategic evaluation.
• The Malaria Vaccine Program (BNT165b1) is currently on clinical hold by the FDA.
• Pfizer and BioNTech have opted out of further joint development of the Shingles Vaccine Program (BNT167).
• BioNTech is involved in numerous ongoing patent litigation cases with Moderna, Arbutus, Genevant, and GlaxoSmithKline, with uncertain outcomes and potential for substantial costs.
• A securities class action lawsuit (Ladewig v. BioNTech SE) was filed, alleging violations of the Exchange Act, although it was dismissed, plaintiffs have the option to appeal.
• The market price of BioNTech ADSs has experienced and may continue to experience significant volatility.
• Acquisitions, joint ventures, and collaborations may increase capital requirements, dilute shareholders, cause debt, or subject the company to other risks.
• The German foreign investment screening regime requires government approval for substantial interest acquisitions by non-EU/non-EFTA investors, potentially limiting demand for BioNTech ADSs.
• Holders of BioNTech ADSs are not treated as direct shareholders and do not have the same voting rights as ordinary shareholders.
• Holders of BioNTech ADSs may not be able to participate in future preemptive subscription rights issues or elect to receive dividends in shares, which could cause additional dilution.

Risks

• Demand for the COVID-19 vaccine is expected to continue decreasing, impacting revenues heavily reliant on its sales.
• Uncertainty in COVID-19 vaccine demand and difficulties in targeting appropriate supply may lead to significant inventory write-downs and cancellations of contract manufacturing orders.
• Successful commercialization of product candidates depends on governmental authorities, private health insurers, and other third-party payors providing coverage and adequate reimbursement levels.
• Failure to increase marketing and sales capabilities, either independently or through third parties, may hinder effective commercialization of product candidates.
• Operating results may fluctuate significantly, making future results difficult to predict and potentially causing the price of ADSs to decline.
• Difficulties in developing and expanding the company, including managing acquisitions and growth, could disrupt operations.
• Business is dependent on the successful development, regulatory approval, and commercialization of product candidates based on technology platforms.
• Clinical development is a lengthy, expensive process with uncertain outcomes, and delays can occur for various reasons outside of control.
• Reliance on information technology systems exposes the company to risks of security breaches, data loss, and other disruptions.
• Manufacturing processes for novel technologies like mRNA are complex and difficult, potentially leading to difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing exposes the company to risks of non-compliance, missed deadlines, or contractual failures.
• Inadequate efforts to obtain, maintain, protect, defend, and enforce intellectual property related to products and technologies may hinder competitive effectiveness.
• Regulatory authorities (FDA, EMA) may disagree with regulatory plans, leading to failure or delays in obtaining approval for product candidates.
• Approved products are subject to continuing regulatory oversight and ongoing obligations, which may result in significant additional expense or penalties for non-compliance.
• Discovery of previously unknown safety issues with products could negatively affect commercialization, lead to approval withdrawal, or product liability claims.
• Government policies (manufacturing, export controls, tariffs) and negative public perception regarding vaccines and mRNA-based therapeutics could severely impact manufacturing and sales.
• Significant competition from other makers of COVID-19 vaccines and broader biopharmaceutical companies may lead to loss of market share.
• The COVID-19 vaccine is sensitive to temperature, shipping, and storage conditions, posing risks of loss or damage.
• Market opportunities for some product candidates may be small due to disease rarity or limited patient populations, affecting profitability.
• Achieving or maintaining profitability depends on penetrating global markets, which involves additional regulatory burdens and international operational risks.
• Market acceptance among physicians, patients, hospitals, and the medical community is crucial for commercial success, even with regulatory approval.
• Coverage and reimbursement for product candidates may be limited or unavailable, making profitable sales difficult.
• Healthcare reform legislation and changes to the regulatory environment could increase costs and affect pricing.
• Drug marketing and reimbursement regulations in the European Union and elsewhere may materially affect the ability to market and receive coverage.
• Long-term sustainable profitability is difficult to achieve and maintain over time and is highly dependent on various factors.
• The company has incurred significant losses in the past and may incur significant losses in the future.
• The amount and ability to use net operating losses and research and development credits to offset future taxable income may be subject to limitations and uncertainty.
• Pending and future tax audits, disputes with tax authorities, and changes in tax law could lead to additional tax liabilities.
• Obligations to withhold wage tax and social security contributions if contract service providers are considered internal employees could lead to penalties and fees.
• Substantial additional financing may be required, and failure to obtain it on acceptable terms could force delays or termination of product development programs.
• International trade obligations, including customs value calculation and tariff classification, may lead to penalties for late payments.
• As a foreign private issuer, the company is exempt from certain U.S. securities laws and Nasdaq rules, which may limit information available to ADS holders and make ADSs less attractive.
• Insurance policies are expensive and may only protect from some business risks, leaving significant uninsured liabilities.
• Adverse developments affecting financial institutions could adversely affect operations and liquidity.
• mRNA drug development carries substantial clinical development and regulatory risks, with the novel nature of product candidates creating further challenges in obtaining regulatory approval.
• Product candidates may not work as intended, cause undesirable effects, or have other properties that could delay or prevent regulatory approval or limit commercial profile.
• Clinical trials are strictly regulated and monitored, and unexpected events may occur that could adversely impact patient safety or regulatory approvals.
• Preclinical development is uncertain, and programs may experience delays or never advance to clinical trials.
• Difficulties enrolling participants in clinical trials could delay or adversely affect clinical development activities.
• Global operations are subject to differing regulatory requirements, unexpected changes in tariffs, economic weakness, and other international risks.
• Interim top-line and preliminary data from studies or trials may change as more data become available and are subject to audit and verification procedures.
• Results of earlier studies and trials of product candidates may not be predictive of future trial results.
• Planned clinical trials may be less efficacious or reveal significant adverse events not seen in preclinical studies.
• Failure to discover, develop, and commercialize additional product candidates beyond the current portfolio would impair business expansion.
• Dependence on single-source or a small number of suppliers for components and materials used in products and product candidates.
• Regulatory and operational risks associated with the physical and digital infrastructure at internal manufacturing facilities and external service providers.
• Certain product candidates are uniquely manufactured for each patient, posing difficulties in production and scaling manufacturing capabilities.
• Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences.
• Inability to effectively monitor and respond to rapid and ongoing developments and expectations relating to environmental, social, and governance (ESG) matters may impose unexpected costs or reputational harm.
• The CureVac Group is exposed to risks relating to an advance purchase agreement with the European Commission, including the risk of repayments and fines, which could affect BioNTech following closing of the Transactions.
• Following the Transactions, BioNTech may be unable to integrate the businesses of BioNTech and the CureVac Group successfully and realize anticipated synergies and other benefits.
• Following the Transactions, BioNTech may be unable to retain key CureVac Group employees.
• Counterparties to certain significant agreements with the CureVac Group may exercise contractual rights under such agreements in connection with the Transactions.
• BioNTech expects to incur substantial expenses related to the Transactions.
• The pendency of the Transactions could adversely affect the business and operations of BioNTech and the CureVac Group.
• The Purchase Agreement contains provisions that could discourage a potential competing acquirer of CureVac or could result in a competing proposal being at a lower price.
• Shareholder litigation against BioNTech and CureVac could result in an injunction preventing completion of the Transactions or payment of damages.
• The company must implement share capital increases to create the Offer Consideration, which will result in an extended settlement and may delay the closing of the Transactions.
• Holders of the BioNTech ADSs are not treated as shareholders of the Company and will not have the same voting rights as the Company's shareholders.
• The acquisition of a substantial interest in the Company by non-EU/non-EFTA investors requires government approval, which may restrict certain investments and limit demand for the BioNTech ADSs.
• The large number of shares eligible for sale or subject to rights requiring registration could cause the market price of the BioNTech ADSs to drop significantly.

Future Outlook

BioNTech aims to become a global immunotherapy powerhouse with multiple approved products and revenue streams, focusing on oncology and sustainable respiratory infectious disease vaccines. The company plans to launch its first oncology product as early as 2026 and continue investing significantly in R&D, global development, and manufacturing capabilities. The strategic partnership with BMS is expected to provide substantial upfront and non-contingent payments, bolstering cash flow and potential milestones. BioNTech anticipates a net loss for 2025, with revenues projected between €1.7 billion and €2.2 billion, R&D expenses between €2.6 billion and €2.8 billion, and sales, general and administrative expenses between €650.0 million and €750.0 million.

Management Comments

• We believe we are a global next-generation immunotherapy company aiming to pioneer novel medicines against cancer, infectious diseases and other serious diseases.
• Our fully integrated model combines decades of research in immunology with a multi-technology innovation engine, Good Manufacturing Practice manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, and machine learning, capabilities to discover, develop and commercialize our marketed product and product candidates.
• We believe our multi-technology combination of platforms and product candidates positions us as pioneers in the field of individualized, patient-centric therapeutic approaches in oncology and infectious diseases.
• Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages.
• The root causes of cancer treatment failure are cancer heterogeneity and interindividual variability. Driven by random sequential mutations, every patient’s cancer is different and within one patient’s tumor, every cell is different. Addressing these two challenges is the core of our strategy.
• To augment anti-tumor activity and to counteract resistance mechanisms, we seek to combine compounds with non-overlapping, potentially synergistic mechanisms of action.
• Our approach has generated a robust and diversified product candidate pipeline across a range of technologies in oncology and infectious disease, and has led to the approval of our first marketed product, Comirnaty.
• The Company's boards believe that the acquisition of CureVac will have significant potential strategic benefits, including that the acquisition will support the global execution of the BioNTech's strategy to develop, manufacture, and commercialize mRNA-based medicines in oncology as well as expand BioNTech's capabilities to research, develop, manufacture, and commercialize mRNA-based medicines as a pan-tumor technology platform in oncology.
• As a result of the transaction, BioNTech will obtain complementary capabilities and proprietary technologies in target discovery, production, mRNA design, and delivery formulations.
• The transaction complements BioNTech's recent acquisitions in its other key pillars in oncology, including immunomodulators like bispecific antibodies and targeted therapies like antibody-drug conjugates.
• BioNTech recognizes the importance of research and development in CureVac's business and intends to maintain investment in research and development in Germany.
• The Company does not expect to report a positive net income figure for the 2025 financial year.
• We aim to further advance our oncology pipeline with the aim of launching our first oncology product on the market as early as 2026 and establishing ourselves as an innovative oncology company with several approved products in various indications by 2030.

Industry Context

BioNTech is strategically positioning itself as a global next-generation immunotherapy company, aiming to pioneer novel medicines against cancer, infectious diseases, and other serious conditions. The acquisition of CureVac is a key move to strengthen its mRNA oncology platform, complementing existing efforts in immunomodulators and antibody-drug conjugates. This aligns with a broader industry trend towards precision medicine and multi-technology approaches in drug development. The company operates in a highly competitive biopharmaceutical market characterized by rapid technological advancements and a complex intellectual property landscape, facing established players like Moderna, Sanofi, and AstraZeneca. BioNTech's significant investments in AI and machine learning reflect the industry's increasing reliance on advanced computational methods for drug discovery and development. The focus on global health threats and equitable access to vaccines also positions BioNTech within the evolving landscape of public health initiatives and partnerships.

Comparison to Industry Standards

• BioNTech's COVID-19 vaccine, Comirnaty, was the first-ever approved mRNA-based product and, to its knowledge, the fastest developed prophylactic vaccine from viral sampling to approval, setting a high benchmark for rapid vaccine development.
• The company's multi-technology combination of platforms and product candidates positions it as pioneers in individualized, patient-centric therapeutic approaches in oncology and infectious diseases, differentiating it from companies focused on single technology modalities.
• BNT327, a bispecific antibody, has shown encouraging anti-tumor activity independent of PD-L1 expression levels, with a positive correlation between higher tumor PD-L1 expression and overall response rates, and a manageable safety profile, potentially offering a differentiated profile compared to typical anti-PD-(L)1 therapies, anti-VEGF therapies, and chemotherapy.
• BNT316/ONC-392, an anti-CTLA-4 monoclonal antibody, is designed to offer higher anti-tumor efficacy and a differentiated safety profile compared to other anti-CTLA-4 antibodies, potentially allowing for higher dosing and longer treatment duration.
• The BioNTainer platform represents an innovative approach to establishing scalable vaccine production, particularly in low-income countries with limited infrastructure, aiming to improve global vaccine supply and address equitable access challenges.
• BioNTech's ESG performance is strong, maintaining Prime status from ISS ESG (Top 10% in pharmaceutical and biotechnology sector) and improving its overall rating from Bto B in the Corporate Rating 2024 by S&P Global, indicating a commitment to sustainability that is competitive within the industry.
• The company's proprietary mRNA manufacturing approach aims to maintain control and flexibility, contrasting with a purely outsourcing strategy, which could offer a competitive advantage in terms of speed and quality control.

Management Changes

Corporate Governance

Legal Proceedings

• Settlement agreement with NIH on December 20, 2024, for $791.5 million, resolving claimed royalties for 2020-2023 and amending the NIH License Agreement.
• Settlement agreement with UPenn on March 27, 2025, for up to $467.0 million, including royalties for 2020-2023, funding for vaccine alliance extension, and contribution to an R&D investment fund.
• GSK/CureVac Settlement Arrangements on August 7, 2025, resolved pending patent litigation in the US, with BioNTech paying $370 million to GSK and $370 million to CureVac, and receiving a non-exclusive license for mRNA-based vaccines.
• Alnylam Settlement Agreement on August 29, 2025, resolved patent litigation, with Alnylam agreeing not to appeal a noninfringement judgment and mutual releases.
• Ongoing infringement lawsuits by CureVac against BioNTech in Dsseldorf Regional Court regarding multiple European patents and German utility models, with some patents found invalid or likely invalid by EPO/German Patent and Trademark Office, and appeals pending.
• Ongoing nullity action by BioNTech in the Federal Patent Court of Germany seeking invalidation of CureVac's EP122 patent (nullified, appeal pending).
• Ongoing cancellation actions by BioNTech in the German Patent and Trademark Office against CureVac's German Utility Models (some cancelled, appeals pending).
• Ongoing declaratory judgment complaint by BioNTech/Pfizer in the U.S. District Court for the Eastern District of Virginia, with CureVac counterclaims for infringement of additional U.S. patents; trial rescheduled for September 8, 2025.
• Ongoing declaration of non-infringement and revocation action by BioNTech/Pfizer in the UK High Court against CureVac's patents (some found invalid, appeal pending).
• Ongoing infringement lawsuits by Moderna against BioNTech and Pfizer in Dsseldorf Regional Court, UK High Court, U.S. District Court for the District of Massachusetts, District Court of The Hague, High Court of Ireland, and Brussels Dutch-speaking Enterprise Court, alleging Comirnaty infringement.
• Ongoing inter partes review proceedings before the United States Patent Trial and Appeal Board (PTAB) initiated by Pfizer and BioNTech against Moderna's U.S. Patent Nos. 10,702,600 and 10,933,127 (found unpatentable/invalid, appeal pending).
• Ongoing lawsuit by Arbutus and Genevant against Pfizer and BioNTech in the U.S. District Court for the District of New Jersey alleging infringement of lipid nanoparticle technology patents.
• Ongoing arbitration initiated by Genevant against BioNTech alleging breach of a license and co-development agreement.
• Ongoing lawsuits by GlaxoSmithKline Biologicals SA against BioNTech and Pfizer entities in the U.S. District Court for the District of Delaware, High Court of Ireland, and Unified Patent Court (Hague Division) alleging Comirnaty infringement.
• Ongoing revocation action by BioNTech and Pfizer against GlaxoSmithKline Biologics SA in the UK High Court, with GSK filing a counterclaim for infringement.
• Ongoing lawsuit by Promosome LLC against BioNTech and Pfizer in the Unified Patent Court (Munich Division) alleging Comirnaty infringes EP 2 401 365.
• Securities class action complaint (Ladewig v. BioNTech SE) filed in the U.S. District Court for the Southern District of New York alleging violations of the Exchange Act; dismissed, but plaintiffs have until October 30, 2025, to appeal.

Related Party Transactions

• ATHOS KG, as the sole shareholder of AT Impf GmbH, exercises de facto control over BioNTech due to its substantial shareholding.
• Purchases of various goods and services from entities controlled by ATHOS KG amounted to €0.2 million in 2024, €0.3 million in 2023, and €0.3 million in 2022.
• Purchases of property and other assets from entities controlled by ATHOS KG amounted to €62.5 million in 2022.
• Outstanding balances of transactions with ATHOS KG or entities controlled by them were €0.4 million as of December 31, 2024, and December 31, 2023.
• Key management personnel compensation for the Management Board was €13.0 million in 2024, €8.3 million in 2023, and €15.0 million in 2022.
• Key management personnel compensation for the Supervisory Board was €0.9 million in 2024, €0.6 million in 2023, and €0.5 million in 2022.
• Prof. Ugur Sahin, M.D. (Chief Executive Officer) and Prof. zlem Treci, M.D. (Chief Medical Officer) are married, representing a family relationship among key management.
• Helmut Jeggle, Chair of the Supervisory Board, holds functions and management positions at BioNTech's (indirect) controlling shareholders and/or affiliates, which constitutes a potential conflict of interest.

Stakeholder Impact

• Shareholders (BioNTech): Will experience dilution from the CureVac acquisition (4.0% to 5.9% decrease in shareholding percentage). Face risks of share price volatility due to market conditions, company performance, and ongoing litigation. The significant control exerted by principal shareholders and management may influence corporate decisions.
• Shareholders (CureVac): Will receive BioNTech ADSs in exchange for their CureVac shares. Those who do not tender their shares may be subject to Dutch dividend withholding tax on the cancellation consideration. Will have less influence over the management and policies of the combined company.
• Employees (BioNTech & CureVac): BioNTech plans to comply with CureVac's existing employment terms and consultation obligations. Workforce adjustments are expected in certain manufacturing sites (Marburg: 250-350 FTE reduction; Idar-Oberstein: 100-200 FTE reduction) and administrative/preclinical research in Europe/North America (550-700 FTE reduction). However, 800-1,200 new FTE positions are expected in other areas. Transaction bonuses of up to $8.9147 million are allocated to CureVac management board members.
• Customers: Will benefit from the continued supply of COVID-19 vaccines, including new variant-adapted versions. Potential for new oncology and infectious disease treatments from the expanded pipeline.
• Suppliers/Partners: Integration of supply chains and potential changes in relationships are expected. Risks of disruptions due to trade policies or manufacturing issues remain.
• Regulatory Bodies: Will continue to scrutinize drug development, manufacturing, and commercialization activities. The company will need to comply with evolving AI regulations.
• Public Health: Benefits from the continued development of vaccines for infectious diseases (COVID-19, influenza, tuberculosis, malaria, mpox, shingles) and cancer immunotherapies. BioNTech maintains a commitment to equitable access to medicines globally.

Next Steps

• BioNTech will continue the CureVac acquisition offer, with the initial offer closing on December 3, 2025.
• BioNTech will recalculate and publish the final Exchange Ratio by November 26, 2025.
• A Subsequent Offering Period will commence on December 4, 2025, for at least 10 business days.
• Resolutions on share capital increases and related share issuances for Offer ADSs are expected on or about December 4, 2025, and December 19, 2025.
• Registration of share capital increases with the commercial register is expected on or about December 15, 2025, and January 2, 2026.
• Delivery of Offer ADSs and cash for fractional shares to tendering CureVac shareholders is expected on or about December 17, 2025, and January 6, 2026.
• BioNTech plans to undertake a detailed strategic review of the CureVac business post-acquisition.
• BioNTech intends to maintain investment in CureVac's R&D in Germany and comply with existing employee consultation obligations and employment terms.
• BioNTech aims to leverage the combined global presence to consolidate minor administrative offices.
• BioNTech aims to launch its first oncology product as early as 2026.
• BioNTech and Pfizer intend to continue monitoring COVID-19 epidemiology and develop modified vaccine formulas as needed.
• BioNTech will continue to develop additional process improvements for mRNA manufacturing to reduce turnaround times.
• BioNTech will work with the FDA to assess next steps for the Malaria Vaccine Program (BNT165b1) clinical hold.
• BioNTech and Pfizer will consider next steps for the wind-down and further advancement of the Shingles Vaccine Program (BNT167).
• BioNTech will continue to monitor developments in AI regulation and assess its applicability to its business.
• BioNTech will continue to drive progress with a focus on its highest potential opportunities and advance its strategic vision.
• CureVac is expected to issue a final audit report within 60 days after October 17, 2025, regarding compliance with the EU Commission APA.
• Plaintiffs in Ladewig v. BioNTech SE have until October 30, 2025, to file a notice of appeal.

Key Dates

Recommendation

BioNTech is undergoing a significant strategic transformation with the acquisition of CureVac and major collaborations like the one with BMS, aiming to diversify its pipeline beyond COVID-19. While these initiatives bring substantial upfront payments and long-term growth potential in oncology and infectious diseases, the company is currently experiencing significant net losses and declining COVID-19 vaccine revenues. The integration of CureVac presents execution risks, and numerous ongoing patent litigations create considerable uncertainty and potential financial outflows. The stock price has shown high volatility, and future performance hinges on successful clinical trial outcomes and market acceptance of new therapies, which are inherently uncertain. Given the mix of strong strategic initiatives and substantial financial resources, but also significant current losses, operational challenges, and legal risks, a 'hold' recommendation is appropriate. Investors should monitor the integration progress, pipeline advancements, and resolution of legal disputes before making further investment decisions.

Keywords

BioNTech, CureVac, Acquisition, mRNA, Oncology, Vaccines, COVID-19, Biopharmaceutical, Immunotherapy, Clinical Trials, SEC Filing, Merger, ADS, BNTX, CVAC, Biotech, Pharmaceutical, Healthcare, Risk Management, Intellectual Property, Financials, Corporate Governance